Proposed general pharmaceutical legislation from the European Commission would not support equitable access to new medicines in the European Union. Instead, this legislation would erode intellectual property (IP) and existing incentives that are essential for Europe’s ability to research, develop, manufacture and deliver innovative treatments to patients. Learn why.